---
version: 1.0
last_updated: 2026-10-23
project: ATS
owner: MA
category: reference
status: active
---
# WI-20261023-ATS-004

Generated using create-wi-handoff-packet after explicit user approval on 2026-10-23 under approved active REQ007.

[WI HEADER]
WI ID: WI-20261023-ATS-004
REQ: REQ-20261011-ATS-007
Agent: DocOps
Depends On: Initial approval now; final WI003 and MA phase1 result
Blocks: -

[WI SUMMARY]
Why: Record approved phase1 scope, then integrate local review and actual account reuse findings.
Scope/DoD/Constraints: Own additive updates to docs/index.md, deliverables/user/REQ-20261011-ATS-007.md and own evidence/user summary. First record user's Oct23 approval verbatim in Korean REQ, execution strategy SE001/SE002 parallel -> PG003 -> MA phase1 -> DocOps004, user-selected Astra Extra High. Do not mark native started/completed without MA receipt. Current permission: local hash implementation/review, server access and necessary DB temporary start/SELECT/stop; app/login/business mutations forbidden; phase2 needs separate approval. Preserve historical content. Final report account reuse results vs unknowns and exact required role/fixture changes, cleanup status, no repeated full auth trial. Scoped docs validation only. Notify MA after initial approval record, then await actual final evidence.

[ACCEPTANCE CRITERIA]
- Functional: complete scoped implementation or evidence, no implied phase2 authority.
- Performance: bounded queries/operations; no full trial replay or unnecessary broad suite.
- Quality: focused tests and exact source/candidate identity; independent review before MA remote mutation.

[INPUT POINTERS]
Tier 0: docs/standards/core-principles.md; docs/standards/documentation-standards.md; docs/standards/development-standards.md; docs/standards/glossary.md.
Tier 1: docs/policies/security-policy.md; docs/policies/quality-gates.md.
Tier 2: deliverables/user/REQ-20261011-ATS-007.md; docs/index.md current entry; deliverables/agent/WI-20261021-ATS-009-evidence-pack.md; deliverables/user/WI-20261021-ATS-012-summary.md.
Injected principles: Korean conversation; English evidence/docs except Korean REQ; approved bounded work only; preserve unrelated work and historical evidence; no secrets/PII in outputs; pointers and measured evidence; source/JAR identity first. Exact user approval on 2026-10-23 supersedes prior local-only restriction only for MA's phase-1 server access and temporary DB start/read/stop. No app, login, business-data mutation, payment, publication, installation, deletion, commit or push. Subagents remain local only.
[TRACEABILITY REQUIREMENTS]
Use create-wi-evidence-pack. Record precise hashes, test commands/results, current versus historical evidence, limits and preservation rollback. No fabrication of operational approval or runtime PASS.

Task pointers: build/WI013-audio-native; build/WI010-audio-trial; build/WI011-audio-review/review-receipt-20261023.json; build/WI067-auth-trial-v8r1; build/WI067-pc-delivery-v8r1; build/WI067-ledger-diagnostic-v2; build/WI068-release-run-02/source-before.json.

[OUTPUT CONTRACT]
Agent-facing: deliverables/agent/WI-20261023-ATS-004-evidence-pack.md.
User-facing: deliverables/user/WI-20261023-ATS-004-summary.md.
Implementation ownership as scoped above. Completion immediately triggers blocked WI; MA owns remote execution.

